The ANSM and the patient protection committee have given their agreement for the restart of Aeson® implantations within the framework of the EFICAS study
Stéphane Piat, CEO of CARMAT, declares: “This approval is very positive news for French patients who will now be able to benefit from Aeson® within the framework of the EFICAS study that we will soon initiate in France. This study is also essential for the Company, as it will allow us to collect essential medico-economic data to support the reimbursement of our therapy, particularly in France. Our teams are actively working to build up stocks of prostheses to support the resumption of our locations in Europe. »
To receive all of CARMAT’s financial information in real time, send a request by email to [email protected]. Your registration will be immediate.